CD274 and neoplasm: If the efficacy of pembrolizumab is confirmed in patients with ≥ 5% PD-L1+ tumor cells characterized by 22C3 in KEYNOTE-181 [22], PD-L1 induction by S-588410 may support combination therapy with a PD-(L)1 antibody.